{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.162","value":"0.371"},{"groupId":"OG001","spread":"0.0894","value":"0.332"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"T1/2,z refers to the time required for the plasma concentration of a drug to decrease by half during the final phase of elimination from the body.","dispersionType":"Standard Deviation","groups":[{"description":"Eligible participants with relapsed or refractory acute lymphoblastic leukemia who had PK assessments on Day 8 of the induction cycle.","id":"OG000","title":"Carfilzomib - Day 8 Induction Cycle"},{"description":"Eligible participants with relapsed or refractory acute lymphoblastic leukemia who had PK assessments on Day 1 of the consolidation cycle.","id":"OG001","title":"Carfilzomib - Day 1 Consolidation Cycle"}],"paramType":"MEAN","populationDescription":"Phase 2 PK analysis set: All participants who received at least 1 dose of carfilzomib, had 1 PK sample collected and a quantifiable number of observations. Per SAP, analysis was not planned to compare T-cell and B-cell.","reportingStatus":"POSTED","timeFrame":"Day 8 of induction cycle (28-days cycle) and Day 1 of consolidation cycle (28-days cycle)","title":"Phase 2: Terminal Half-life (t1/2,z) of Carfilzomib","type":"SECONDARY","unitOfMeasure":"hour"}